Lane Frey, MD
Endocrinology, Diabetes & Metabolism · Thibodaux, LANPI 1932337052
Payments from drug & device makers
Across 574 payments — averaging $351.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$165K
- Boehringer Ingelheim$24K
- Lilly USA, LLC$8K
- AstraZeneca$445
- Amgen$392
- Sanofi-aventis U.S. LLC$346
- plus $3K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 266 | $165,321 |
| Boehringer Ingelheim | 57 | $24,194 |
| Lilly USA, LLC | 51 | $8,388 |
| AstraZeneca | 15 | $445 |
| Amgen(2 entities) | 18 | $392 |
| Sanofi-aventis U.S. LLC | 19 | $346 |
| Abbott | 18 | $342 |
| Dexcom, Inc. | 12 | $234 |
| Xeris Pharmaceuticals, Inc. | 12 | $225 |
| Corcept Therapeutics | 8 | $169 |
| Bayer | 8 | $155 |
| AbbVie | 10 | $153 |
| IBSA Pharma Inc. | 7 | $131 |
| Antares Pharma, Inc. | 7 | $126 |
| Medtronic(2 entities) | 7 | $122 |
| Tandem Diabetes Care, Inc. | 5 | $113 |
| Insulet Corporation | 5 | $106 |
| BETA Bionics, Inc. | 5 | $106 |
| Tolmar, Inc. | 4 | $86 |
| Amneal Pharmaceuticals LLC | 5 | $84 |
| Merck | 5 | $79 |
| Novartis | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $53 |
| Recordati_rare_diseases_inc. | 3 | $51 |
| Nevro Corp. | 3 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $45 |
| Johnson & Johnson | 3 | $43 |
| BD | 2 | $41 |
| Shire North American Group Inc | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $25 |
| Cequr Corporation | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $17 |
| Valeritas, Inc. | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
How this compares
$201,859 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Thibodaux
- Tuan Huy TranMetairie$2M
- Harold MillerHammond$1.1M
- Timothy GilbertBaton Rouge$985K
- Justin FontenotLafayette$905K
- Vivian FonsecaNew Orleans$700K
- Frank GreenwayBaton Rouge$669K
- Abdul KhanHammond$587K
- Ileana TandronSlidell$527K
- Jonathan WiseMetairie$463K
- Marideli ScanlanMarrero$446K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.